Therapeutic antibodies vary depending on production system

July 10, 2018, University of Natural Resources and Life Sciences, Vienna

Differences in production methods for therapeutic antibodies can lead to variations in their structure, depending on the recombinant procedure selected. The distinctions, which are based on a number of glycosylations, even impact antibodies' stability. This was the result of a high-precision comparison of the structural properties of antibody isotopes that were manufactured in cell cultures or plants. Equipment BOKU (EQ BOKU) based at the University of Natural Resources and Life Sciences, Vienna (BOKU) employed state-of-the-art mass spectrometers to pinpoint minute differences in the glycosylation of immunoglobulins.

Antibodies are one of the most precise forms of medicine and are increasingly being used to combat cancer and other conditions. They are frequently produced recombinantly, with a range of different manufacturing processes in use. Each process creates an identical protein scaffold in the antibody, but there are differences in what is known as , or modification by adding specific carbohydrates. Previously, little was known about the way in which these differences come about and the form they take. Identifying these subtle, but potentially medically significant distinctions requires extremely complex analysis, which is only possible using the latest procedures. A BOKU team had access to such equipment at the university's EQ BOKU facility and unearthed some surprising results.

The team headed by Prof. Richard Strasser is the first to identify precise differences in the glycosylation patterns of immunoglobulin A, which had been produced either in human (HEK293) or plant systems (Nicotiana benthamiana). Prof. Strasser, a member of the Department of Applied Genetics and Cell Biology, commented: "Even we were surprised by how big the differences were. There were sharp contrasts between the two systems in terms of the structure of the carbohydrates used for glycosylation and their position on the proteins."

With the help of ultra-modern techniques called capillary reversed-phase chromatography and electrospray mass spectrometry provided by EQ, the team managed to analyse glycosylation in each system down to the finest detail. They found that the immunoglobulin A produced in the HEK293 cell culture had many more and also more complex N-glycans – a group of carbohydrates that bond with particular nitrogen atoms – than that produced in mammalian cell cultures. The immunoglobulin A manufactured in plants also had a significantly narrower range of structures. This was primarily due to the fact that plants have none of the metabolic pathways required for mammalian glycosylation. "But we also saw glycosylations in the manufactured in plants which can only occur in plants," Prof. Strasser added.

Although the glycosylations in the antibodies produced in N. benthamiana were purely plant-specific, the antibodies displayed the same bonding properties for antigens as those manufactured using human cells. This suggests that as far as therapeutic applications are concerned, the choice of production system makes no difference. However, further analysis by Prof. Strasser's team revealed that the stability of immunoglobulin A varies depending on the production method – a factor which could have a decisive effect on its use in treatment. The analysis involved testing the antibodies' thermal stability, which turned out to be lower in immunoglobulin A produced in . "We need to carry out further tests to discover how significant this is for the application of these antibodies in treatment," Prof. Strasser explained.

His team has all the necessary resources to do just that at EQ BOKU. Cutting-edge mass spectrometers, chromatography procedures and calorimeters – and the know-how of BOKU's experts – are all available to the university's research teams, as well as to users from industry and other academic institutions.

Explore further: Hitting virus infections where it hurts

Related Stories

Hitting virus infections where it hurts

April 30, 2018

Virus infection starts at the cell surface with interactions between viral and host proteins that bind together. Researchers are working on ways to lock out the virus or prevent it from reproducing in the cell by targeting ...

Hydrocarbon-degrading fungus yields its secrets

November 29, 2017

Thanks to genes acquired from bacteria, a fungus can degrade an environmentally harmful hydrocarbon - and comes under considerable stress in the process. These remarkable research findings, which were published recently, ...

Expanding the reach of therapeutic antibodies

August 29, 2017

A group of researchers has developed an approach to efficiently produce antibodies that can bind to two different target molecules simultaneously, a long-desired innovation in the field of cancer immunotherapy. The details ...

Recommended for you

New targets in the battle against antibiotic resistance

November 16, 2018

Bacteria are increasingly resistant to available antibiotics. A team of chemists from the Technical University of Munich (TUM) have now identified important enzymes in the metabolism of staphylococci. Blocking these enzymes ...

AI heralds new frontiers for predicting enzyme activity

November 16, 2018

Researchers from the Departments of Chemistry and Engineering Science at the University of Oxford have found a general way of predicting enzyme activity. Enzymes are the protein catalysts that perform most of the key functions ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.